Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 23, 2024

Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

Episodes in this series

EP. 1 Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

EP. 1 Advancing IgA Nephropathy Care: Emerging Therapies, Unmet Needs, and Economic Considerations

4 experts are featured in this series.

EP. 2 Introduction to IgA Nephropathy

4 experts are featured in this series.

EP. 3 Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines

4 experts are featured in this series.

EP. 4 Diagnosing IgA Nephropathy

4 experts are featured in this series.

EP. 5 Signs and Symptoms of IgA Nephropathy

4 experts are featured in this series.

EP. 6 Challenges in Timely Identification of IgA Nephropathy

4 experts are featured in this series.

EP. 7 Clinical Impact of IgA Nephropathy and Quality of Life

4 experts are featured in this series.

EP. 8 Overview of Treatment Landscape for IgA Nephropathy: Standard of Care and KDIGO Guidelines

4 experts are featured in this series.

EP. 9 Current Treatments for IgA Nephropathy and the 4-Hit Cascade

4 experts are featured in this series.

EP. 10 Gaps in Patient Care for IgA Nephropathy

4 experts are featured in this series.

EP. 11 Emerging Anti-BAFF and Anti-APRIL Therapies

4 experts are featured in this series.

EP. 12 Emerging Therapies: Other Strategies and Important Considerations

4 experts are featured in this series.

EP. 13 The Promise of Emerging Therapies for IgA Nephropathy and Future KDIGO Guidelines

4 experts are featured in this series.

EP. 14 Sequencing and Individualizing Treatments for IgA Nephropathy

4 experts are featured in this series.

EP. 15 Measuring Success in IgA Nephropathy in Clinical Practice

4 experts are featured in this series.

EP. 16 Economic Impact of IgA Nephropathy for Patients

4 experts are featured in this series.

EP. 17 Early Diagnosis and Cost Mitigation in IgA Nephropathy

4 experts are featured in this series.

EP. 18 Cost Implications of Modulating IgA Nephropathy Disease Course

4 experts are featured in this series.

EP. 19 Patient-Reported Outcomes in the Treatment of IgA Nephropathy

4 experts are featured in this series.

EP. 20 Future Possibilities for Step Therapy in IgA Nephropathy Treatment

4 experts are featured in this series.

EP. 21 Key Managed Care Considerations for IgA Nephropathy Treatment

4 experts are featured in this series.

EP. 22 Key Economic Considerations in IgA Nephropathy: Progression to Chronic Kidney Disease

4 experts are featured in this series.

EP. 23 Closing Thoughts About IgA Nephropathy Treatment

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective

ByMazen Noureddin, MD, MHSc

July 24th 2026

Advanced Treatments, Biologic Cycling, and Head-to-Head Data in Atopic Dermatitis

ByAngela J. Lamb, MD

July 24th 2026

Transplants, Decompensation, and the True Cost of Untreated MASH

ByNadege Gunn, MD

July 24th 2026

The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 20th 2026

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

ByNadege Gunn, MD

July 17th 2026

Trending on AJMC

Jeff Hunnicutt to Bring Community Oncology Roots to New Role as Navista COO

Contributor: State Leaders Need Real-World Evidence to Integrate Social Care at Scale

New MINT Trial Analysis Favors Liberal Transfusion After MI

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

Drug Development-to-Reimbursement Timelines Show Little Progress Over a Decade